Changes in Beneficial Ownership · 4
Medicus Pharma Ltd.
MDCXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
es260854075_4-bokhari.xml
Filing details
- Report period
- 2026-11-13
- Issuer
- Medicus Pharma Ltd.
- Issuer CIK
- 0001997296
- Trading symbol
- MDCX
Reporting owner 1
- Name
- Bokhari Raza
- Reporting owner CIK
- 0001660525
- Relationship
- Director · Officer · 10% owner
- Officer title
- Chief Executive Officer
- Address
- 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN, PA, 19428
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par value | 2026-11-13 | A · Form 4[F1] | 436,046 | A | 1.72 | 451,909 | I | See Footnote[F2] |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- On November 13, 2026, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with the Issuer, pursuant to which RBx Capital, LP agreed to purchase 436,046 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements.↩ 1
- F2
- Held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.↩ 1
Signature 1
- Signed
- /s/ Raza Bokhari
- Date
- 2026-11-17
Company context
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").
Current securities
Recent company filings
- SCHEDULE 13D/A - filed by Bokhari Raza regarding Medicus Pharma Ltd.Nov 17, 2026
- 4 filingNov 17, 2026
- 4 filingNov 17, 2026
- 424B3 filingNov 16, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Other EventsNov 16, 2026